New blood clot drug tested in humans for first time

NCT ID NCT06665828

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety of a new drug called REGN9533 in 72 healthy adults. REGN9533 is a monoclonal antibody that blocks factor XII, a protein involved in blood clotting. The goal was to see if it is safe and how the body processes it, before testing it in people with blood clot disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN9533 (a monoclonal antibody that blocks factor XII, a protein involved in blood clotting)
What this could lead to: If successful, this could lead to a new treatment to prevent dangerous blood clots (thromboembolic diseases) with potentially fewer bleeding risks than current options.
What could go wrong: This is a very early Phase 1 trial in only 72 healthy people, so it is not designed to prove effectiveness. The drug may cause unexpected side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

SGS Belgium NV_Edegem

Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.